NEW YORK (GenomeWeb) – Investment Bank Cowen and Co. today downgraded shares of GenMark Diagnostics to Market Perform and reduced the price target to $7.25 over concerns with the firm's ability to bring its newest platform to market on time.
Already have a GenomeWeb or 360Dx account?Login Now.
What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.
A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.